The core activity of GlycoEra is the development of innovative biologics based on a glycoengineering platform, particularly for the treatment of autoimmune diseases and neurological disorders through protein degradation.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of novel biologics for the selective removal of disease-causing proteins, with an initial focus on autoimmune diseases and other protein-driven conditions.
Protein Targeting and Degradation
Protein targeting and degradation of circulating extracellular and membrane proteins to remove disease-causing proteins quickly, deeply and selectively from circulation.
Autoimmune Disease Programs
Programs for the treatment of autoimmune diseases, in particular against circulating autoantibodies, with the first program GE8820 for pathogenic IgG4 autoantibodies.
Platform for Extracellular Protein Degraders
Platform for the development of bifunctional biologics for the degradation of extracellular and membrane-bound proteins; designed for fast, deep and selective target engagement.
Partnerships for Pipeline Development
Partnerships with industrial companies to expand the impact of the platform and to develop additional programs against circulating proteins.